On November 18, 2026, two insiders at Moderna, Inc. (MRNA) executed significant share sales, totaling approximately $15.79 million. Stephen Hoge, President of Moderna, sold a combined 73,136 shares across two transactions. The first sale involved 39,160 shares at an average price of $219.66 per share, amounting to roughly $8.60 million. The second transaction saw Mr. Hoge sell 33,976 shares at an average price of $211.45 per share, totaling approximately $7.18 million.
These transactions come amidst a period of insider selling activity for Mr. Hoge, who has made several sales in recent weeks. While insider sales can be motivated by various personal financial decisions, such as portfolio diversification or tax planning, a series of sales by multiple executives can sometimes draw investor attention.
Moderna, Inc. operates in the biotechnology sector, focusing on messenger RNA (mRNA) therapeutics and vaccines. The company has been at the forefront of mRNA technology development, with a pipeline spanning infectious diseases, oncology, and rare genetic diseases.